JP2022529727A - Ａｎｔｉ－ｃｄ１１７ とその使用 - Google Patents

Ａｎｔｉ－ｃｄ１１７ とその使用 Download PDF

Info

Publication number
JP2022529727A
JP2022529727A JP2021562914A JP2021562914A JP2022529727A JP 2022529727 A JP2022529727 A JP 2022529727A JP 2021562914 A JP2021562914 A JP 2021562914A JP 2021562914 A JP2021562914 A JP 2021562914A JP 2022529727 A JP2022529727 A JP 2022529727A
Authority
JP
Japan
Prior art keywords
antigen
linker
cells
binding
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021562914A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020219748A5 (https=
JP2022529727A5 (https=
Inventor
パルチョウデュリー ラーフル
ボイタノ アンソニー
クック マイケル
アール ピアース ブラッドリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianthus Therapeutics Inc
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of JP2022529727A publication Critical patent/JP2022529727A/ja
Publication of JPWO2020219748A5 publication Critical patent/JPWO2020219748A5/ja
Publication of JP2022529727A5 publication Critical patent/JP2022529727A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021562914A 2019-04-24 2020-04-23 Ａｎｔｉ－ｃｄ１１７ とその使用 Withdrawn JP2022529727A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962838255P 2019-04-24 2019-04-24
US62/838,255 2019-04-24
US201962841739P 2019-05-01 2019-05-01
US62/841,739 2019-05-01
PCT/US2020/029618 WO2020219748A2 (en) 2019-04-24 2020-04-23 Anti-cd117 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2022529727A true JP2022529727A (ja) 2022-06-23
JPWO2020219748A5 JPWO2020219748A5 (https=) 2022-09-20
JP2022529727A5 JP2022529727A5 (https=) 2022-09-20

Family

ID=72941301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562914A Withdrawn JP2022529727A (ja) 2019-04-24 2020-04-23 Ａｎｔｉ－ｃｄ１１７ とその使用

Country Status (4)

Country Link
US (1) US20220177578A1 (https=)
EP (1) EP3959243A4 (https=)
JP (1) JP2022529727A (https=)
WO (1) WO2020219748A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
WO2022187050A1 (en) * 2021-03-01 2022-09-09 BioLegend, Inc. Anti-cd117 agents and compositions and methods for making and using the same
WO2023111311A1 (en) * 2021-12-16 2023-06-22 Universität Basel Discernible cell surface protein variants of cd117 for use in cell therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540443B2 (en) * 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
NZ710929A (en) * 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
WO2015050959A1 (en) * 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015067667A1 (en) * 2013-11-05 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Human neutralizing anti-kit antibodies and uses thereof
US10786578B2 (en) * 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
CA3079215A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
WO2019234694A2 (en) * 2018-06-07 2019-12-12 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (adcs)

Also Published As

Publication number Publication date
WO2020219748A2 (en) 2020-10-29
EP3959243A2 (en) 2022-03-02
EP3959243A4 (en) 2023-04-12
US20220177578A1 (en) 2022-06-09
WO2020219748A3 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
CN111372608B (zh) 用于耗尽cd117+细胞的组合物和方法
JP2022530089A (ja) 抗ｃｄ４５抗体薬物結合体とその利用法
JP2022512778A (ja) 抗－ｃｄ４５抗体及びそのコンジュゲート
JP2022529726A (ja) Ａｎｔｉ－ｃｄ１１７とその使用
CN111601616A (zh) 用于耗尽cd117+细胞的组合物和方法
TWI904109B (zh) 抗ｃｄ４５抗體及其結合物
KR20210081393A (ko) Fc 침묵 항체 약물 컨쥬게이트(ADC) 및 이의 용도
JP2021504412A (ja) Ｃｄ５＋細胞の枯渇のための組成物および方法
JP2021500375A5 (https=)
JP2022529726A5 (https=)
JP2022530438A (ja) 抗ｃｄ１１７抗体薬物複合体およびその使用
JP2022530443A (ja) 抗ｃｄ１１７抗体薬物複合体およびその使用
US20220175946A1 (en) Conditioning methods for gene therapy
JP2021504414A (ja) Ｃｄ２＋細胞の枯渇のための組成物および方法
JP2022530443A5 (https=)
JP2022530442A (ja) アントラサイクリン抗体薬物複合体およびその使用
US20220177578A1 (en) Anti-cd117 antibodies and uses thereof
JP2022518150A (ja) 細胞療法での抗ｃｄ４５抗体－薬物結合体（ａｄｃ）の使用経験
JP2022529727A5 (https=)
CN115397444A (zh) 用于同种异体移植的组合物和方法
JPWO2020219770A5 (https=)
JPWO2020219775A5 (https=)
JPWO2020219778A5 (https=)
JPWO2020219774A5 (https=)
JP2021517133A (ja) 抗ｃｄ２５２抗体、コンジュゲート、および使用方法

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230419

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231017